Progyny, Inc. (NASDAQ:PGNY) Shares Bought by Nuveen Asset Management LLC

Nuveen Asset Management LLC grew its stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 38.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 295,979 shares of the company's stock after buying an additional 82,087 shares during the quarter. Nuveen Asset Management LLC owned 0.35% of Progyny worth $5,106,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC lifted its holdings in shares of Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after buying an additional 594,140 shares during the period. Baillie Gifford & Co. lifted its holdings in shares of Progyny by 52.2% in the 4th quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock valued at $22,989,000 after buying an additional 456,853 shares during the period. Vanderbilt University acquired a new position in shares of Progyny in the 4th quarter valued at about $254,000. Janney Montgomery Scott LLC acquired a new position in shares of Progyny in the 4th quarter valued at about $1,124,000. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Progyny by 129.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 19,967 shares of the company's stock valued at $344,000 after buying an additional 11,268 shares during the period. Institutional investors and hedge funds own 94.93% of the company's stock.

Progyny Trading Down 3.1%

Progyny stock traded down $0.68 during mid-day trading on Wednesday, hitting $21.30. The company's stock had a trading volume of 1,102,378 shares, compared to its average volume of 1,706,974. The stock's fifty day moving average is $22.07 and its two-hundred day moving average is $20.24. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $30.42. The firm has a market capitalization of $1.83 billion, a PE ratio of 36.72, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm had revenue of $324.04 million for the quarter, compared to analyst estimates of $307.86 million. During the same quarter last year, the company earned $0.17 earnings per share. The firm's revenue for the quarter was up 16.5% on a year-over-year basis. On average, equities analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on PGNY. Bank of America upped their price target on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Canaccord Genuity Group dropped their price target on Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Finally, BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a research report on Monday, March 31st. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Progyny currently has an average rating of "Hold" and a consensus price target of $23.45.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.